Mutual of America Capital Management LLC Decreases Position in Amgen Inc. (NASDAQ:AMGN)

Mutual of America Capital Management LLC decreased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,316 shares of the medical research company's stock after selling 1,957 shares during the period. Mutual of America Capital Management LLC's holdings in Amgen were worth $21,368,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of AMGN. Capital International Investors lifted its stake in shares of Amgen by 547.8% in the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company's stock worth $1,991,738,000 after acquiring an additional 5,923,915 shares in the last quarter. Pathway Financial Advisers LLC lifted its stake in shares of Amgen by 33,125.4% in the third quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock worth $1,437,115,000 after acquiring an additional 4,446,757 shares in the last quarter. International Assets Investment Management LLC lifted its stake in shares of Amgen by 6,812.4% in the third quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company's stock worth $8,130,610,000 after acquiring an additional 2,486,882 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Amgen by 137.1% in the first quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company's stock worth $676,984,000 after acquiring an additional 1,377,007 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Amgen by 561.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,539,733 shares of the medical research company's stock worth $496,117,000 after acquiring an additional 1,306,982 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Performance

Shares of AMGN stock opened at $283.61 on Friday. Amgen Inc. has a 12-month low of $260.52 and a 12-month high of $346.85. The firm has a market capitalization of $152.45 billion, a price-to-earnings ratio of 36.31, a price-to-earnings-growth ratio of 2.69 and a beta of 0.60. The business has a 50 day simple moving average of $320.85 and a 200 day simple moving average of $318.36. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business's revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the company posted $4.96 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date of this dividend is Monday, November 18th. Amgen's payout ratio is currently 115.24%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research reports. Sanford C. Bernstein initiated coverage on Amgen in a research note on Thursday, October 17th. They set an "outperform" rating and a $380.00 price objective on the stock. Robert W. Baird restated an "underperform" rating and set a $215.00 price objective on shares of Amgen in a research note on Wednesday, September 25th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. UBS Group cut their price objective on Amgen from $335.00 to $326.00 and set a "neutral" rating on the stock in a research note on Thursday, October 31st. Finally, Oppenheimer restated an "outperform" rating and set a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Amgen has a consensus rating of "Moderate Buy" and an average price target of $333.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.